Home  |  About SITC  |  Contact Us

Abstracts

Each year the SITC Annual Meeting showcases highly significant timely findings, ground breaking data and high impact results. Regular abstract submission for the SITC 27th Annual Meeting was available through July 11, 2012.  Late-breaking abstract submission was available through August 22, 2012. All accepted abstracts were presented at the SITC 27th Annual Meeting, October 26-28, 2012 in North Bethesda, MD.

Abstract Categories

• Adoptive T Cell Transfer and Cell Therapy as Cancer Immunotherapy (CARS)
• Combining Immunotherapy and Other Therapies
• DC Subsets/Cancer Vaccines
• Immunity of Oncolytic Viruses
• Immunotherapy Combinations
• Innate Immunity in Cancer
• Single Cell High Throughput Technologies Immune Monitoring
• T Cell Manufacture and Potency Testing
• T Cell Modulating Strategies
• Targeted Therapies and Anti-Tumor Immunity
• Targeting Immune Suppression
• Therapeutic Monoclonal Antibodies in Cancer
• Tumor Microenvironment
• Tumor Vasculature, Chemokines and Lymphocyte Trafficking to the Tumor

Guidelines for Authors

Authors that submitted late-breaking abstracts to the SITC 27th Annual Meeting agreed to the following:

• Serve as the contact for all correspondence about the abstract and inform co-authors about its status.
• Confirm all authors are aware of and agree to the content and data presented in the abstract.
• Verify the abstract is accurate and that permission has been obtained from all relevant parties.
• Verify the data presented in the abstract has not been published prior to the SITC 27th Annual Meeting.
• Provide and verify that the disclosure provided with the abstract for the presenting author is accurate.
• Agree that, if accepted, they or a co-author will present the abstract at the SITC 27th Annual Meeting.